https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/717924 Fri, 14 Mar 2025 11:00:00 -0400 https://www.bioworld.com/articles/717924-liquid-biopsy-market-flooded-with-opportunity Liquid biopsy illustration http://www.bioworld.com/articles/717923 Fri, 14 Mar 2025 11:00:00 -0400 https://www.bioworld.com/articles/717923-samsung-life-science-fund-invests-10m-in-c2n-diagnostics Gold dollar sign JCO Precision Oncology demonstrated.]]> http://www.bioworld.com/articles/711638 Fri, 30 Aug 2024 12:00:00 -0400 https://www.bioworld.com/articles/711638-grails-galleri-puts-aggressive-prostate-cancer-on-display Galleri instruction booklet on blood draw chair Grail’s Galleri multicancer early detection test. http://www.bioworld.com/articles/710924 Mon, 29 Jul 2024 12:00:00 -0400 https://www.bioworld.com/articles/710924-guardant-wins-nod-from-fda-for-shield-test-for-colorectal-cancer guardant bloodkit Guardant Health blood testing kit. Credit: Courtesy Guardant Health Inc. http://www.bioworld.com/articles/698774 Tue, 11 Jul 2023 12:00:00 -0400 https://www.bioworld.com/articles/698774-novigenix-reports-new-data-for-its-technology-used-in-early-colorectal-cancer-detection Test tubes with dropper Novigenix ColoxNGS, the first commercially available immuno-transcriptomics blood-based test. Credit: Novigenix SA http://www.bioworld.com/articles/520843 Tue, 19 Jul 2022 13:00:00 -0400 https://www.bioworld.com/articles/520843-future-looks-bright-with-delfi-diagnostics-225m-round-for-early-cancer-detection-assays Delfi employee pipetting in the lab Inside Delfi Diagnostics Inc.’s laboratory. http://www.bioworld.com/articles/517759 Fri, 08 Apr 2022 13:00:00 -0400 https://www.bioworld.com/articles/517759-c2i-reports-european-launch-of-its-minimal-residual-disease-diagnostic Cancer cell and DNA http://www.bioworld.com/articles/516094 Tue, 15 Feb 2022 13:00:00 -0500 https://www.bioworld.com/articles/516094-datar-wins-breakthrough-designation-for-prostate-cancer-blood-test Dropper and test tubes The Trinetra-Glio blood test is based on the identification of circulating glial cell. Credit: Datar Cancer Genetics Ltd. http://www.bioworld.com/articles/516045 Mon, 14 Feb 2022 13:00:00 -0500 https://www.bioworld.com/articles/516045-inivata-study-highlights-liquid-biopsy-potential-in-hnscc-disease-detection Blood sample, DNA http://www.bioworld.com/articles/515835 Mon, 07 Feb 2022 13:00:00 -0500 https://www.bioworld.com/articles/515835-study-demonstrates-pan-cancer-detection-from-genetic-and-epigenetic-biomarkers Cancer cells under magnifying glass http://www.bioworld.com/articles/515747 Thu, 03 Feb 2022 13:00:00 -0500 https://www.bioworld.com/articles/515747-biocaptiva-gears-up-to-test-dna-capture-device-in-clinical-trials DNA illustration http://www.bioworld.com/articles/515623 Mon, 31 Jan 2022 13:00:00 -0500 https://www.bioworld.com/articles/515623-liquid-biopsy-comes-to-nash-as-liver-disease-explodes Illustration of liver, blood vial overlaid on woman's silhouette Glympse's noninvasive liquid biopsy uses biosensors to monitor NASH progression. Credit: Glympse Bio Inc. http://www.bioworld.com/articles/515174 Fri, 14 Jan 2022 12:00:00 -0500 https://www.bioworld.com/articles/515174-liquid-biopsy-panel-debates-value-of-individual-cancer-screening-tests Cancer cell and DNA The $24.68 per share offered by Quidel represents a nearly 25% premium over Ortho’s closing price as of Dec. 22. Quidel will also assume $2 billion in debt. In addition, Laboratory Corp. of America Holdings (Labcorp) said it would acquire Baltimore-based Personal Genome Diagnostics Inc., which offers a portfolio of genomics-based liquid biopsy and tissue-based diagnostic products, for $450 million in cash at closing plus up to $125 million contingent on achieving specific performance milestones. That deal is also expected to close in the first half of 2022, pending approval by both companies’ shareholders.]]> http://www.bioworld.com/articles/514605 Mon, 27 Dec 2021 13:00:00 -0500 https://www.bioworld.com/articles/514605-two-diagnostic-deals-valued-at-a-combined-65b-close-out-2021 Chess board and pieces, blocks spelling out M&A http://www.bioworld.com/articles/512954 Tue, 02 Nov 2021 13:00:00 -0400 https://www.bioworld.com/articles/512954-astrazeneca-and-saga-diagnostics-link-up-for-assay-development-agreement Handshake with DNA, molecules Plos One study are borne out in larger trials and the test gets the nod from the FDA. That is a lot of ifs, but the study posted strong results: 100% specificity and 92.2% sensitivity for cancer and 95% specificity and 62.5% sensitivity for precancerous lesions.]]> http://www.bioworld.com/articles/512810 Wed, 27 Oct 2021 13:00:00 -0400 https://www.bioworld.com/articles/512810-coloscape-demonstrates-100-specificity-for-colorectal-cancer Illustration of DNA, digestive system http://www.bioworld.com/articles/512536 Tue, 19 Oct 2021 13:00:00 -0400 https://www.bioworld.com/articles/512536-inivata-hopes-new-trials-will-help-bring-its-lung-cancer-liquid-biopsies-into-routine-use Lung cancer illustration http://www.bioworld.com/articles/512476 Mon, 18 Oct 2021 13:00:00 -0400 https://www.bioworld.com/articles/512476-berry-oncology-shows-promising-data-on-early-screening-for-six-cancers Cancer cells under magnifying glass http://www.bioworld.com/articles/512343 Wed, 13 Oct 2021 13:00:00 -0400 https://www.bioworld.com/articles/512343-twist-and-anchordx-co-launch-pan-cancer-detection-solution-globally Cancer cell, DNA illustration http://www.bioworld.com/articles/511254 Thu, 09 Sep 2021 13:00:00 -0400 https://www.bioworld.com/articles/511254-savicell-touts-high-accuracy-results-for-its-liquid-biopsy-platform Cancer cell, DNA illustration http://www.bioworld.com/articles/511205 Wed, 08 Sep 2021 12:00:00 -0400 https://www.bioworld.com/articles/511205-illumina-links-up-with-merck-for-companion-diagnostic-tests-for-cancer-mutation Business people with hands atop a digital globe http://www.bioworld.com/articles/511160 Tue, 07 Sep 2021 13:00:00 -0400 https://www.bioworld.com/articles/511160-illumina-links-up-with-merck-for-companion-diagnostic-tests-for-cancer-mutation Business people with hands atop a digital globe http://www.bioworld.com/articles/510471 Mon, 16 Aug 2021 13:00:00 -0400 https://www.bioworld.com/articles/510471-anchordx-wins-fdas-breakthrough-device-designation-for-bladder-cancer-test Bladder cancer illustration http://www.bioworld.com/articles/509638 Thu, 22 Jul 2021 13:00:00 -0400 https://www.bioworld.com/articles/509638-lunit-secures-26m-in-funding-and-reveals-future-guardant-partnership Brandon Suh and Helmy Eltoukhy shaking hands Brandon Suh, CEO of Lunit, and Helmy Eltoukhy, CEO of Guardant Health. Credit: Lunit Inc. http://www.bioworld.com/articles/509636 Thu, 22 Jul 2021 13:00:00 -0400 https://www.bioworld.com/articles/509636-foresight-diagnostics-phased-seq-detects-circulating-tumor-dna-at-extremely-low-levels Foresight research associate in the lab Credit: Foresight Diagnostics Inc. http://www.bioworld.com/articles/507031 Wed, 12 May 2021 13:00:00 -0400 https://www.bioworld.com/articles/507031-caris-life-sciences-gets-830m-injection-for-precision-oncology-platform David Spetzler holding microscope slide David Spetzler, president and chief scientific officer of Caris Life Sciences Inc. http://www.bioworld.com/articles/506820 Thu, 06 May 2021 13:00:00 -0400 https://www.bioworld.com/articles/506820-neogenomics-moves-up-bid-to-buy-liquid-biopsy-specialist-inivata-for-390m Illustration of big fish eating three smaller fish http://www.bioworld.com/articles/505528 Mon, 05 Apr 2021 13:00:00 -0400 https://www.bioworld.com/articles/505528-invitae-snaps-up-genosity-for-200m-reports-115b-investment Deal illustration http://www.bioworld.com/articles/505479 Thu, 01 Apr 2021 13:00:00 -0400 https://www.bioworld.com/articles/505479-bluestar-genomics-gets-breakthrough-nod-for-pancreatic-cancer-screening-test Pancreas illustration http://www.bioworld.com/articles/505429 Wed, 31 Mar 2021 13:00:00 -0400 https://www.bioworld.com/articles/505429-ftc-throws-up-antitrust-hurdle-to-illuminas-planned-acquisition-of-grail One dice with a green checkmark, red X and gray question mark.